Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (se deschide o fereastră nouă)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Sursă‎: Ann Intern Med 2008;148(12):939-55.

Index‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (se deschide o fereastră nouă)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (se deschide o fereastră nouă)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Sursă‎: Am J Hematol 2000;64(1):26-31.

Index‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (se deschide o fereastră nouă)

Hydroxyurea for the treatment of sickle cell anemia. (se deschide o fereastră nouă)

Platt OS.

Sursă‎: N Engl J Med 2008;358(13):1362-9.

Index‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (se deschide o fereastră nouă)

Clinical effectiveness of decitabine in severe sickle cell disease. (se deschide o fereastră nouă)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Sursă‎: Br J Haematol 2008;141(1):126-9.

Index‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (se deschide o fereastră nouă)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (se deschide o fereastră nouă)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Sursă‎: Blood 2010;115(12):2354-63.

Index‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (se deschide o fereastră nouă)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (se deschide o fereastră nouă)

Hirst C, Owusu-Ofori S.

Sursă‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Index‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (se deschide o fereastră nouă)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (se deschide o fereastră nouă)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Sursă‎: Lancet Haematol 2021;8(5):e323-33.

Index‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (se deschide o fereastră nouă)

Sickle cell disease. (se deschide o fereastră nouă)

Meremikwu MM, Okomo U.

Sursă‎: BMJ Clin Evid 2011;02:2402.

Index‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (se deschide o fereastră nouă)

A phase 3 trial of l-glutamine in sickle cell disease. (se deschide o fereastră nouă)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Sursă‎: N Engl J Med 2018;379(3):226-35.

Index‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (se deschide o fereastră nouă)

Malaria chemoprophylaxis in sickle cell disease. (se deschide o fereastră nouă)

Oniyangi O, Omari AA.

Sursă‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Index‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (se deschide o fereastră nouă)